secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bellerophon Therapeutics, Inc. (—)
CIK:        0001600132
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001104659-23-120348
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Bellerophon appoints Craig Jalbert President/principal officer amid wind-down; CEO leaves Nov 15
--------------------------------------------------------------------------------

- CEO Peter Fernandes and VP Parag Shah separated effective Nov 15, 2023, per previously disclosed separation agreements.
- Craig Jalbert appointed President, Treasurer, Corporate Secretary, principal executive/financial/accounting officer, and director.
- Jalbert, a distressed-business specialist at Verdolino & Lowey, will be compensated $10k/month pre-dissolution, then $50k/year for three years post-dissolution.
- Compensation structure is contingent on stockholder approval of dissolution and board decision to implement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/tm2331228d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-120348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer